Connect with us

Health

‘I’m a pediatrician: I get these top 11 questions about measles’

Published

on

‘I’m a pediatrician: I get these top 11 questions about measles’

As measles cases continue to spread throughout the U.S. — with 12 states reporting official outbreaks, according to the latest CDC data — concern is growing among high-risk groups.

Children under the age of 5 are most vulnerable to measles, health experts confirm.

The CDC recommends that children receive two doses of the MMR (measles-mumps-rubella) vaccine, starting with the first dose at 12 to 15 months of age, and a second dose at 4 through 6 years of age. 

MEASLES OUTBREAKS EMERGE ACROSS US: SEE WHICH STATES HAVE REPORTED CASES

That means children under 5 may not have full protection.

Advertisement

As measles cases continue to spread throughout the U.S. — with 12 states reporting official outbreaks, according to the latest CDC data — concern is growing among high-risk groups. (iStock)

Allison Croucher, DO, a pediatrician and doctor of osteopathic medicine with Duly Health and Care in Illinois, said she frequently gets questions from concerned parents looking to protect their children from the highly contagious virus.

Chroucher shared some of the most common inquiries she receives, along with her responses.

1. Should I be worried about measles where I live or where I’m traveling to?

Measles cases have been reported in 20 states so far (according to the CDC): Alaska, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Montana, New Jersey, New Mexico, New York City, New York State, Ohio, Oklahoma, Pennsylvania, Rhode Island, Tennessee, Texas, Vermont, Virginia and Washington.

Baby with measles

Children under the age of 5 are most vulnerable to measles, health experts confirm. (iStock)

Even if you do not live in one of those areas, keep a close eye on local health alerts, since the disease is rapidly evolving. 

Advertisement

Your state’s Department of Health website, which should end in “.gov,” is a great place to start. If you plan on traveling to an area with reported cases, be sure to seek guidance from your doctor beforehand.

2. How do I know if my child is fully vaccinated?

A child is considered fully vaccinated for measles if they have received two doses of the measles, mumps and rubella (MMR) vaccine at least four weeks apart. 

The first dose is typically given to children between 12 and 15 months old, followed by the second at four to six years.

Child at pediatrician

In the early stages, symptoms to watch out for include fever, cough, runny nose, and red, irritated eyes.  (iStock)

3. Can my infant get the vaccine early? 

In certain cases, yes. Infants who are high-risk or traveling to areas with active cases may be eligible to get the MMR vaccine between six months and 12 months of age. This depends on individual circumstances, so it’s important to talk with your pediatrician. 

Keep in mind that an early dose doesn’t count on the regular vaccination schedule — your child will still need two additional doses after their first birthday.

Advertisement

ANOTHER STATE CONFIRMS MEASLES CASE WITH INFECTED CHILD ITS FIRST OF YEAR

4. What if my infant is too young to get the MMR vaccine? 

If your infant is too young for the vaccine, it’s important to take extra precautions to limit their exposure to others who are or might be ill. Don’t be afraid to decline travel or gatherings — you have every right to protect your child’s health.

5. How early can my child get their second MMR vaccine? 

For children over one year, the second MMR dose can be given as early as four weeks after the first. Once they’ve received both doses, children are considered fully vaccinated and don’t require any additional doses.

“One to three of every 1,000 children infected with measles will die due to complications from the disease.”

6. We have been around other people who recently traveled. What symptoms should we watch for?  

In the early stages, symptoms to watch out for include fever, cough, runny nose, and red, irritated eyes. 

Advertisement

These symptoms usually appear seven to 14 days after initial exposure. 

7. My child is showing signs of a cold. Could this be early-stage measles?

It’s not always easy to tell, since measles shares symptoms with many other illnesses. One key differentiator is that children with measles typically display very high fevers, around 104°F. They also tend to be very fussy. 

Around the second or third day of symptoms, many patients develop small, bluish-white spots on their inner cheeks, referred to as Koplik spots — though not every child will develop these spots. The telltale red rash typically develops three to five days into the illness.

Measles outbreak across America

A child is considered fully vaccinated for measles if they have received two doses of the measles, mumps and rubella (MMR) vaccine at least four weeks apart.  (Jan Sonnenmair/Getty Images)

8. What does the measles rash look like? 

This rash typically starts three to five days after the initial symptoms. It begins as small spots on the face near the hairline, then spreads downwards and can cover the entire body.

Advertisement

9. Why is measles dangerous? 

Measles can have many complications, ranging from mild to severe. About one in 10 people will develop ear infections or diarrhea. 

About one in five unvaccinated children with measles will require hospitalization. Up to one in 20 children will contract pneumonia, which is the most common cause of death from the disease. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

About one in 1,000 children will develop encephalitis, or inflammation and swelling of the brain. This can lead to seizures, lifelong disability or even death. In all, one to three of every 1,000 children infected with measles will die due to complications from the disease.

10. Why aren’t some people getting their kids the MMR vaccine? 

There is a growing amount of misinformation and disinformation circulating about vaccines, which has led some parents to delay or skip them altogether. 

Advertisement

The MMR vaccine has been safely administered to millions of people and has an excellent safety record — and research has repeatedly debunked the myth that the vaccine is linked to autism. 

For more Health articles, visit www.foxnews.com/health

11. What should I do if I think my child might have the measles? 

Don’t wait — contact your doctor right away. They can guide you through the next steps.

The above questions and answers were provided by Allison Croucher, DO, a pediatrician and doctor of osteopathic medicine with Duly Health and Care in Illinois.

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Health

We Tried Three Doctor-Approved, Ozempic-Friendly Recipes | Woman's World

Published

on

We Tried Three Doctor-Approved, Ozempic-Friendly Recipes | Woman's World


Advertisement


We Tried Three Doctor-Approved, Ozempic-Friendly Recipes | Woman’s World




























Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Continue Reading

Health

Weight-loss medications may also benefit common medical problem, study finds

Published

on

Weight-loss medications may also benefit common medical problem, study finds

Weight-loss medications known as glucagon-like peptide-1 (GLP-1) agonists, which have gained popularity for treating type 2 diabetes and obesity, have been shown to have the surprising secondary benefit of reducing alcohol intake.

A team of international researchers from Ireland and Saudi Arabia followed 262 adult patients with obesity who started taking two GLP-1 medications: liraglutide or semaglutide.

Among the regular drinkers, weekly alcohol intake decreased by 68%, from approximately 23 units of alcohol to around 8 units.

WEIGHT LOSS, DIABETES DRUGS CAN CAUSE MOOD CHANGES: WHAT TO KNOW ABOUT BEHAVIORAL SIDE EFFECTS

The findings were recently published in the journal Diabetes, Obesity and Metabolism and were also presented last week at the European Congress on Obesity in Spain.

Advertisement

GLP-1 agonists mimic a hormone called GLP-1, which is released from the gastrointestinal system after eating, according to study co-author Carel Le Roux, a professor at University College Dublin.

Weight-loss medications known as glucagon-like peptide-1 (GLP-1) agonists have been shown to have the surprising secondary benefit of reducing alcohol intake. (iStock)

These medications activate GLP-1 receptors in the brain, decreasing the sense of “reward” people feel after eating or drinking, eventually leading to reduced cravings for both food and alcohol, he told Fox News Digital.

“It is this commonality of function that suggests the GLP-1 receptors in the brain may be a therapeutic target for not just the disease of obesity, but also for alcohol use disorder,” the professor said.

Study findings

Before the participants started the weight-loss drugs, they self-reported their weekly alcohol intake, then were categorized as non-drinkers, rare drinkers or regular drinkers.

Advertisement

Approximately 72% had at least two follow-up visits and 68% reported regular alcohol consumption.

WEIGHT-LOSS DRUGS’ IMPACT ON CANCER RISK REVEALED IN NEW STUDY

After starting the weight-loss medications, the participants’ weekly average alcohol intake decreased by almost two-thirds overall — from approximately 11 units of alcohol to four units after four months of treatment with the GLP-1 agonists.

The reduction in alcohol use was comparable to the decrease that can be achieved by nalmefene, a drug that decreases the “buzz” feeling in people with alcohol use disorder in Europe, according to the researchers.

Man drinking alcohol

Among the regular drinkers, weekly alcohol intake decreased by 68%, from approximately 23 units of alcohol to around 8 units. (iStock)

For the 188 patients who were followed over an average of four months, none had increased their alcohol intake after starting the weight-loss medications.

Advertisement

Patients reported that after an evening meal, they were too full to have their usual drink — and when they did drink, they reported becoming full extremely quickly and drinking at a slower pace, Le Roux noted.

“The findings in this study suggest that we may have just found a therapeutic target for alcohol use disorder.”

This suggests that the experience was less enjoyable, partly due to the reduced rate of alcohol absorption.

Some patients also reported that they didn’t enjoy the flavor of the alcoholic beverages as much, and also that hangovers were much worse.

All of these experiences showed that the weight-loss medications create “guard rails” that prevent most patients from drinking excessively, giving them a degree of control over their alcohol intake, according to Le Roux.

Advertisement
Woman drinking wine

After starting the weight-loss medications, the participants’ weekly average alcohol intake decreased by almost two-thirds overall. (iStock)

“The findings in this study suggest that we may have just found a therapeutic target for alcohol use disorder — the GLP-1 receptor,” the professor told Fox News Digital.

“This finding potentially opens the possibility of an entirely new pharmacological treatment paradigm, which could be used in conjunction with conventional methods, such as behavior therapy and group support.”

Potential limitations

The study was limited by its relatively small number of patients, the researchers acknowledged.

Also, the researchers were not able to verify the participants’ self-reported alcohol intake, and roughly one-third of them were not available for follow-up.

SEMAGLUTIDE FOUND TO HAVE SHOCKING BENEFIT FOR LIVER DISEASE PATIENTS IN NEW STUDY

Advertisement

There was also no control group, which means the researchers couldn’t prove that taking weight-loss medication reduces alcohol intake.

A woman prepares to administer an insulin injection

The main advantage of GLP-1 agonists is that they only need to be taken once a week and continue to work for the entire week. (iStock)

“Randomized, controlled trials with diverse patient populations — including patients diagnosed with alcohol use disorder — are needed to provide the quality and quantity of data that could be used to support an application for licensing the medication for the treatment of alcohol use disorder,” Le Roux said.

(One such trial is currently underway in Denmark.)

Study implications

With the current medications available to treat alcohol use disorder, the “major problem” is compliance, Le Roux said — “because the cravings for alcohol tend to come in waves.”

Advertisement

“This means a patient might be fully committed to treatment at one point in the week, but then stop taking the medication later in the week when a craving comes,” the professor added.

two wine glasses

“This research suggests a promising ancillary benefit of GLP-1 analogs, potentially influencing cravings for alcohol and offering a new avenue for managing alcohol use disorder,” a physician said. (iStock)

There are currently three FDA-approved medications to treat alcohol use disorder: naltrexone (which helps decrease cravings by reducing the “buzz” feeling that comes with drinking alcohol); disulfiram (which helps some people avoid alcohol by making them feel sick when they drink), and acamprosate (which restores the balance of hormones in the brain to reduce cravings), according to the National Institute on Alcohol Abuse and Alcoholism.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

But less than 10% of people with alcohol use disorder get the proper treatment, with many resuming use within the first year of treatment, past research shows.

The main advantage of the GLP-1 agonists is that they only need to be taken once a week and continue to work for the entire week.

Advertisement
Close-up of Ozempic pens and person injecting needle in background

For the 188 patients who were followed over an average of four months, none had increased their alcohol intake after starting the weight-loss medications. (iStock)

Outside experts say the study’s findings highlight the potential of weight-loss medications to help treat alcohol use disorder.

“This research suggests a promising ancillary benefit of GLP-1 analogs, potentially influencing cravings for alcohol and offering a new avenue for managing alcohol use disorder,” Dr. Fatima Cody Stanford, obesity medicine physician at Massachusetts General Hospital and Harvard Medical School, who was not part of the study, told Fox News Digital.

For more Health articles, visit www.foxnews.com/health

“While the exact mechanisms are still being explored, the findings contribute to our understanding of the broader benefits of GLP-1 analogs beyond obesity treatment,” Stanford added.

Advertisement
Continue Reading

Health

Surgeons Perform First Human Bladder Transplant

Published

on

Surgeons Perform First Human Bladder Transplant

Surgeons in Southern California have performed the first human bladder transplant, introducing a new, potentially life-changing procedure for people with debilitating bladder conditions.

The operation was performed earlier this month by a pair of surgeons from the University of California, Los Angeles, and the University of Southern California on a 41-year-old man who had lost much of his bladder capacity from treatments for a rare form of bladder cancer.

“I was a ticking time bomb,” the patient, Oscar Larrainzar, said on Thursday during a follow-up appointment with his doctors. “But now I have hope.”

The doctors plan to perform bladder transplants in four more patients as part of a clinical trial to get a sense of outcomes like bladder capacity and graft complications before pursuing a larger trial to expand its use.

Dr. Inderbir Gill, who performed the surgery along with Dr. Nima Nassiri, called it “the realization of a dream” for treating thousands of patients with crippling pelvic pain, inflammation and recurrent infections.

Advertisement

“There is no question: A potential door has been opened for these people that did not exist earlier,” said Dr. Gill, the chairman of the urology department at U.S.C.

Until now, most patients who undergo a bladder removal have a portion of their intestine repurposed to help them pass urine. Some receive an ileal conduit, which empties urine into a bag outside the abdomen, while others are given a so-called neobladder, or a pouch tucked inside the body that attaches to the urethra and allows patients to urinate more traditionally.

But bowel tissue, riddled with bacteria, is “inherently contaminated,” Dr. Gill said, and introducing it to the “inherently sterile” urinary tract leads to complications in up to 80 percent of patients, ranging from electrolyte imbalances to a slow reduction in kidney function. The loss of the intestinal segment can also cause new digestive issues.

Dr. Despoina Daskalaki, a transplant surgeon at Tufts Medical Center who was not involved in the new procedure, said advances in transplant medicine (from critical life-sustaining organs, like hearts and livers, to other body parts, like faces, hands, uteri and penises) had led doctors to start “pushing the envelope.”

“They’re asking: ‘Why do we have to put up with all the complications? Why don’t we try and give this person a new bladder?’” Dr. Daskalaki said.

Advertisement

In late 2020, Dr. Nassiri was in his fourth year of residency at the University of Southern California when he and Dr. Gill sat down in the hospital cafeteria to begin brainstorming approaches. After Dr. Nassiri began a fellowship on kidney transplantation at U.C.L.A., the two surgeons continued working together across institutions to test both robotic and manual techniques, practicing first on pigs, then human cadavers, and finally, human research donors who no longer had brain activity but maintained a heartbeat.

One of the challenges of transplanting a bladder was the complex vascular infrastructure. The surgeons needed to operate deep inside the pelvis of the donor to capture and preserve a rich supply of blood vessels so the organ could thrive inside the recipient.

“When we’re removing a bladder because of cancer, we basically just cut them. We do it in less than an hour on a near-daily basis,” Dr. Gill said. “For a bladder donation, that is a significantly higher order of technical intensity.”

The surgeons also chose to conjoin the right and left arteries — as well as the right and left veins — while the organ was on ice, so that only two connections were needed in the recipient, rather than four.

When their strategy was perfected in 2023, the two drew up plans for a clinical trial, which eventually would bring the world’s first recipient: Oscar.

Advertisement

When Mr. Larrainzar walked into Dr. Nassiri’s clinic in April 2024, Dr. Nassiri recognized him. Almost four years earlier, Mr. Larrainzar, a husband and father of four, had been navigating end-stage kidney disease and renal cancer, and Dr. Nassiri helped remove both of his kidneys.

But Mr. Larrainzar had also survived urachal adenocarcinoma, a rare type of bladder cancer, and a surgery to resect the bladder tumor had left him “without much of a bladder at all,” Dr. Nassiri said. A normal bladder can hold more than 300 cubic centimeters of fluid; Mr. Larrainzar’s could hold 30.

Now, years of dialysis had begun to fail; fluid was building up inside his body. And with so much scarring in the abdominal region, it would have been difficult to find enough usable length of bowel to pursue another option.

“He showed up serendipitously,” Dr. Nassiri said, “but he was kind of an ideal first candidate for this.”

On a Saturday night earlier this month, Dr. Nassiri received a call about a potential bladder match for Mr. Larrainzar. He and Dr. Gill drove straight to the headquarters of OneLegacy, an organ procurement organization, in Azusa, Calif., and joined a team of seven surgeons working overnight to recover an array of organs from a donor.

Advertisement

The two brought the kidney and bladder to U.C.L.A., then stopped home for a shower, breakfast and a short nap. They completed the eight-hour surgery to give Mr. Larrainzar a new bladder and kidney later that day.

Dr. Nassiri said that kidney transplants can sometimes take up to a week to process urine, but when the kidney and bladder were connected inside Mr. Larrainzar, there was a great connection — “immediate output” — and his creatinine level, which measures kidney function, started to improve immediately. Mr. Larrainzar has already lost 20 pounds of fluid weight since the surgery.

The biggest risks of organ transplantation are the body’s potential rejection of the organ and the side effects caused by the mandatory immune-suppressing drugs given to prevent organ rejection. That is why, for Dr. Rachel Forbes, a transplant surgeon at Vanderbilt University Medical Center who was not involved in the procedure, the excitement is more tempered.

“It’s obviously a technical advance,” she said, but “we already have existing options for people without bladders, and without the downside of requiring immunosuppression.” Unless a patient is — like Mr. Larrainzar — going to be on those medications anyway, “I would be a little bit nervous that you would be exchanging some complications for others,” she said.

A new bladder transplant also does not have nerve connections in the recipient, so while it works well as a storage organ, doctors did not know whether Mr. Larrainzar would ever be able to sense a full bladder, let alone hold and empty it naturally. They spoke about catheters, abdomen maneuvers and eventually developing an on-demand bladder stimulator to help with the release.

Advertisement

But at a follow-up appointment on Thursday morning — just two days after Mr. Larrainzar was discharged from the hospital — Dr. Nassiri removed the catheter and gave him fluids, and Mr. Larrainzar immediately felt that he could urinate.

Dr. Nassiri called it a miracle, then phoned Dr. Gill, who was in a U.S.C. operating room, and exclaimed two words: “He peed!”

“No way! What the hell?” Dr. Gill said. “My jaw is on the floor.”

After finishing the surgery, Dr. Gill drove straight to U.C.L.A. and watched Mr. Larrainzar do it again.

“Of course, this is very, very early. Let’s see how everything goes,” Dr. Gill cautioned. “But it’s the first time he has been able to pee in seven years. For all of us, this is huge.”

Advertisement

Mr. Larrainzar, exhausted, smiled, and Dr. Nassiri brought him a bottle of mineral water to celebrate.

Continue Reading
Advertisement

Trending